At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCWB HCW Biologics Inc.
Market Closed 08-07 16:00:00 EDT
3.41
+0.00
0.00%
盘后3.40
-0.01-0.29%
19:50 EDT
High3.57Low3.30Vol51.91K
Open3.41D1 Closing3.41Amplitude7.92%
Mkt Cap5.45MTradable Cap4.81MTotal Shares1.60M
T/O178.57KT/O Rate3.68%Tradable Shares1.41M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Top Brass Makes Bold Move on HCW Biologics Shares
TIPRANKS  ·  08-01
Top Brass Makes Bold Move on HCW Biologics Shares
HCW Biologics Director Scott T. Garrett Acquires 7,736 Common Shares for $19,995.56
Reuters  ·  08-01
HCW Biologics Director Scott T. Garrett Acquires 7,736 Common Shares for $19,995.56
HCW Biologics Issues 400,000 Pre-funded Warrants in $1.6 Million Private Placement
Reuters  ·  07-29
HCW Biologics Issues 400,000 Pre-funded Warrants in $1.6 Million Private Placement
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
THOMSON REUTERS  ·  07-29
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
HCW Biologics Seeks FDA Pre-ind Meeting for Hcw11-018b T-cell Engager Program
Reuters  ·  07-23
HCW Biologics Seeks FDA Pre-ind Meeting for Hcw11-018b T-cell Engager Program
HCW Biologics - Requests Type B Pre-ind Meeting with FDA for Hcw11-018b
THOMSON REUTERS  ·  07-23
HCW Biologics - Requests Type B Pre-ind Meeting with FDA for Hcw11-018b
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-generation T-cell Engager Program on Track to Initiate Clinical Trials in First Half 2027
THOMSON REUTERS  ·  07-23
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-generation T-cell Engager Program on Track to Initiate Clinical Trials in First Half 2027
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
GlobeNewswire  ·  07-23
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
HCW Biologics Resolves Disputes, Clears Miramar Property Liens
TIPRANKS  ·  07-01
HCW Biologics Resolves Disputes, Clears Miramar Property Liens
HCW Biologics - Pays in Full Amounts Owed to Eirgenix Under Settlement Agreement on May 26, 2026 - SEC Filing
THOMSON REUTERS  ·  07-01
HCW Biologics - Pays in Full Amounts Owed to Eirgenix Under Settlement Agreement on May 26, 2026 - SEC Filing
HCW Biologics - to Report Settlement of $2.8 Mln Disputed Accounts Payable in Q2 2026 - SEC Filing
THOMSON REUTERS  ·  07-01
HCW Biologics - to Report Settlement of $2.8 Mln Disputed Accounts Payable in Q2 2026 - SEC Filing
HCW Biologics - B&I Contractors Files Voluntary Dismissal with Prejudice Against HCW Biologics on June 26, 2026 - SEC Filing
THOMSON REUTERS  ·  07-01
HCW Biologics - B&I Contractors Files Voluntary Dismissal with Prejudice Against HCW Biologics on June 26, 2026 - SEC Filing
HCW Biologics Says B&I Contractors Drops Florida Lien Crossclaims, Settles Dispute over USD 1.1 Million Lien
Reuters  ·  07-01
HCW Biologics Says B&I Contractors Drops Florida Lien Crossclaims, Settles Dispute over USD 1.1 Million Lien
HCW Biologics regains compliance with Nasdaq
TIPRANKS  ·  06-30
HCW Biologics regains compliance with Nasdaq
HCW Biologics Executes 1-for-6 Reverse Stock Split
Reuters  ·  06-30
HCW Biologics Executes 1-for-6 Reverse Stock Split
HCW Biologics Regained Compliance with Bid Price Rule Per NASDAQ Compliance Letter
THOMSON REUTERS  ·  06-30
HCW Biologics Regained Compliance with Bid Price Rule Per NASDAQ Compliance Letter
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
GlobeNewswire  ·  06-30
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
Hcw Biologics Inc trading halted, news pending
TIPRANKS  ·  06-30
Hcw Biologics Inc trading halted, news pending
HCW Biologics Effects 1-for-6 Reverse Stock Split June 30
Reuters  ·  06-26
HCW Biologics Effects 1-for-6 Reverse Stock Split June 30
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
THOMSON REUTERS  ·  06-26
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
No data available

Introduction

Company Name.
HCW Biologics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Issue price:
--